Company Profile

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Latest News

Boeing (BA) To Report Earnings Tomorrow: Here Is What To Expect

StockStory • 07/27/2026

United Pursued Delta Merger: Report. Airline Stocks Are Rising for a Different Reason.

Barrons.com • 07/27/2026

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565

PR Newswire • 07/27/2026

Ponce Financial: Q2 Earnings Snapshot

Associated Press • 07/27/2026

UK TV comedy star and naturalist Bill Oddie dies at 85

AFP • 07/27/2026